BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

650 related articles for article (PubMed ID: 27803041)

  • 1. Association Between Duration of Dual Antiplatelet Therapy and Angiographic Multivessel Disease on Outcomes in Patients Treated With Newer-Generation Drug-Eluting Stents.
    Lee SY; Hong MK; Shin DH; Kim JS; Kim BK; Ko YG; Choi D; Jang Y; Kim HS; Valgimigli M; Colombo A; Gilard M; Palmerini T; Stone GW
    Circ Cardiovasc Interv; 2016 Nov; 9(11):. PubMed ID: 27803041
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety of an abbreviated duration of dual antiplatelet therapy (≤6 months) following second-generation drug-eluting stents for coronary artery disease: A systematic review and meta-analysis of randomized trials.
    Ziada KM; Abdel-Latif AK; Charnigo R; Moliterno DJ
    Catheter Cardiovasc Interv; 2016 Mar; 87(4):722-732. PubMed ID: 26309050
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 6- Versus 24-Month Dual Antiplatelet Therapy After Implantation of Drug-Eluting Stents in Patients Nonresistant to Aspirin: Final Results of the ITALIC Trial (Is There a Life for DES After Discontinuation of Clopidogrel).
    Didier R; Morice MC; Barragan P; Noryani AAL; Noor HA; Majwal T; Hovasse T; Castellant P; Schneeberger M; Maillard L; Bressolette E; Wojcik J; Delarche N; Blanchard D; Jouve B; Ormezzano O; Paganelli F; Levy G; Sainsous J; Carrie D; Furber A; Berlan J; Darremont O; Le Breton H; Lyuycx-Bore A; Gommeaux A; Cassat C; Kermarrec A; Cazaux P; Druelles P; Dauphin R; Armengaud J; Dupouy P; Champagnac D; Ohlmann P; Ben Amer H; Kiss RG; Ungi I; Gilard M
    JACC Cardiovasc Interv; 2017 Jun; 10(12):1202-1210. PubMed ID: 28641840
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Duration of dual antiplatelet therapy after implantation of the first-generation and second-generation drug-eluting stents.
    Yu X; Chen F; He J; Gao Y; Wu C; Luo Y; Zhang X; Zhang Y; Ren X; Lv S
    Coron Artery Dis; 2013 May; 24(3):217-23. PubMed ID: 23425771
    [TBL] [Abstract][Full Text] [Related]  

  • 5. One-Month Dual Antiplatelet Therapy Following Percutaneous Coronary Intervention With Zotarolimus-Eluting Stents in High-Bleeding-Risk Patients.
    Kandzari DE; Kirtane AJ; Windecker S; Latib A; Kedhi E; Mehran R; Price MJ; Abizaid A; Simon DI; Worthley SG; Zaman A; Choi JW; Caputo R; Kanitkar M; McLaurin B; Potluri S; Smith T; Spriggs D; Tolleson T; Nazif T; Parke M; Lee LC; Lung TH; Stone GW;
    Circ Cardiovasc Interv; 2020 Nov; 13(11):e009565. PubMed ID: 33167705
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prediction of Ischemic and Bleeding Events Using the Dual Antiplatelet Therapy Score in an Unrestricted Percutaneous Coronary Intervention Population.
    Brener SJ; Kirtane AJ; Rinaldi MJ; Stuckey TD; Witzenbichler B; Weisz G; Neumann FJ; Metzger DC; Henry TD; Cox DA; Duffy PL; Mazzaferri EL; Gurbel PA; Brodie BR; Mehran R; McAndrew T; Stone GW
    Circ Cardiovasc Interv; 2018 Oct; 11(10):e006853. PubMed ID: 30354629
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of Sex on 2-Year Clinical Outcomes in Patients Treated With 6-Month or 24-Month Dual-Antiplatelet Therapy Duration: A Pre-Specified Analysis From the PRODIGY Trial.
    Gargiulo G; Ariotti S; Santucci A; Piccolo R; Baldo A; Franzone A; Magnani G; Marino M; Esposito G; Windecker S; Valgimigli M
    JACC Cardiovasc Interv; 2016 Sep; 9(17):1780-9. PubMed ID: 27544007
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Benefit of Prolonged Dual Antiplatelet Therapy After Implantation of Drug-Eluting Stent for Coronary Bifurcation Lesions: Results From the Coronary Bifurcation Stenting Registry II.
    Jang WJ; Ahn SG; Song YB; Choi SH; Chun WJ; Oh JH; Cho SW; Kim BS; Yoon JH; Koo BK; Yu CW; Jang YS; Tahk SJ; Kim HS; Gwon HC; Lee SY; Hahn JY
    Circ Cardiovasc Interv; 2018 Jul; 11(7):e005849. PubMed ID: 30006330
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Short-Term Versus Long-Term Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation in Elderly Patients: A Meta-Analysis of Individual Participant Data From 6 Randomized Trials.
    Lee SY; Hong MK; Palmerini T; Kim HS; Valgimigli M; Feres F; Colombo A; Gilard M; Shin DH; Kim JS; Kim BK; Ko YG; Choi D; Jang Y; Stone GW
    JACC Cardiovasc Interv; 2018 Mar; 11(5):435-443. PubMed ID: 29454730
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adjunctive cilostazol versus double-dose clopidogrel after drug-eluting stent implantation: the HOST-ASSURE randomized trial (Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis-Safety & Effectiveness of Drug-Eluting Stents & Anti-platelet Regimen).
    Park KW; Kang SH; Park JJ; Yang HM; Kang HJ; Koo BK; Park BE; Cha KS; Rhew JY; Jeon HK; Shin ES; Oh JH; Jeong MH; Kim S; Hwang KK; Yoon JH; Lee SY; Park TH; Moon KW; Kwon HM; Chae IH; Kim HS
    JACC Cardiovasc Interv; 2013 Sep; 6(9):932-42. PubMed ID: 24050860
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dual Antiplatelet Therapy for 6 Versus 18 Months After Biodegradable Polymer Drug-Eluting Stent Implantation.
    Nakamura M; Iijima R; Ako J; Shinke T; Okada H; Ito Y; Ando K; Anzai H; Tanaka H; Ueda Y; Takiuchi S; Nishida Y; Ohira H; Kawaguchi K; Kadotani M; Niinuma H; Omiya K; Morita T; Zen K; Yasaka Y; Inoue K; Ishiwata S; Ochiai M; Hamasaki T; Yokoi H;
    JACC Cardiovasc Interv; 2017 Jun; 10(12):1189-1198. PubMed ID: 28641838
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 6-Month Versus 12-Month Dual-Antiplatelet Therapy Following Long Everolimus-Eluting Stent Implantation: The IVUS-XPL Randomized Clinical Trial.
    Hong SJ; Shin DH; Kim JS; Kim BK; Ko YG; Choi D; Her AY; Kim YH; Jang Y; Hong MK;
    JACC Cardiovasc Interv; 2016 Jul; 9(14):1438-46. PubMed ID: 27212028
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Validating Utility of Dual Antiplatelet Therapy Score in a Large Pooled Cohort From 3 Japanese Percutaneous Coronary Intervention Studies.
    Yoshikawa Y; Shiomi H; Watanabe H; Natsuaki M; Kondo H; Tamura T; Nakagawa Y; Morimoto T; Kimura T
    Circulation; 2018 Feb; 137(6):551-562. PubMed ID: 28982692
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness analysis of short-duration dual antiplatelet therapy with newer drug-eluting stent platforms versus longer-duration dual antiplatelet therapy with a second-generation drug-eluting stent in elective percutaneous coronary intervention.
    Galper BZ; Reynolds MR; Garg P; Secemsky EA; Valsdottir LR; Cohen DJ; Yeh RW
    Coron Artery Dis; 2019 May; 30(3):177-182. PubMed ID: 30676386
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Polymer-free Biolimus A9-coated stents in the treatment of de novo coronary lesions with short DAPT: 9-month angiographic and clinical follow-up of the prospective, multicenter BioFreedom USA clinical trial.
    Waksman R; Piegari GN; Kabour A; Cannon L; Wang J; Adams G; Solankhi N; Smeglin A; Kereiakes DJ; Leiboff R; Spad MA; Torguson R; Chandra N; Bastian R; DeGroot J; Kayo MW; Stoll HP; Garcia-Garcia HM
    Cardiovasc Revasc Med; 2017; 18(7):475-481. PubMed ID: 28923692
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of six versus 12 months of dual antiplatelet therapy in patients with drug-eluting stent implantation after risk stratification with the residual SYNTAX score: Results from a secondary analysis of the I-LOVE-IT 2 trial.
    Qiu M; Li Y; Li J; Xu K; Jing Q; Dong S; Jin Z; Zhao P; Xu B; Han Y
    Catheter Cardiovasc Interv; 2017 Mar; 89(S1):565-573. PubMed ID: 28211603
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Duration of dual antiplatelet therapy following drug-eluting stent implantation: A systemic review and meta-analysis of randomized controlled trials with longer follow up.
    Sharma A; Agrawal S; Garg A; Vallakati A; Lavie CJ; Helft G
    Catheter Cardiovasc Interv; 2017 Jul; 90(1):31-37. PubMed ID: 28557264
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is Bare-Metal Stent Implantation Still Justifiable in High Bleeding Risk Patients Undergoing Percutaneous Coronary Intervention?: A Pre-Specified Analysis From the ZEUS Trial.
    Ariotti S; Adamo M; Costa F; Patialiakas A; Briguori C; Thury A; Colangelo S; Campo G; Tebaldi M; Ungi I; Tondi S; Roffi M; Menozzi A; de Cesare N; Garbo R; Meliga E; Testa L; Gabriel HM; Ferlini M; Vranckx P; Valgimigli M;
    JACC Cardiovasc Interv; 2016 Mar; 9(5):426-36. PubMed ID: 26965932
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and Safety of Guideline-Recommended Risk Score-Directed Dual Antiplatelet Therapy After 2nd-Generation Drug-Eluting Stents.
    Jang JY; Lee BK; Kim JS; Shin DH; Hong SJ; Ahn CM; Kim BK; Ko YG; Choi D; Hong MK; Park KW; Gwon HC; Kim HS; Kwon HM; Jang Y
    Circ J; 2020 Jan; 84(2):161-168. PubMed ID: 31839621
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early Strut Coverage in Patients Receiving Drug-Eluting Stents and its Implications for Dual Antiplatelet Therapy: A Randomized Trial.
    Lee SY; Kim JS; Yoon HJ; Hur SH; Lee SG; Kim JW; Hong YJ; Kim KS; Choi SY; Shin DH; Nam CM; Kim BK; Ko YG; Choi D; Jang Y; Hong MK
    JACC Cardiovasc Imaging; 2018 Dec; 11(12):1810-1819. PubMed ID: 29454763
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.